Ignite Creation Date:
2025-12-24 @ 6:35 PM
Ignite Modification Date:
2026-01-01 @ 5:59 PM
Study NCT ID:
NCT05745857
Status:
UNKNOWN
Last Update Posted:
2023-02-27
First Post:
2023-02-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Oral Bevacizumab-800CW and Cetuximab-800CW Administration to Detect Early Esophageal Adenocarcinomas
Sponsor:
University Medical Center Groningen
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-05
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12
Completion Date Type:
ESTIMATED
First Submit Date:
2023-02-02
First Submit QC Date:
None
Study First Post Date:
2023-02-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-24
Last Update Post Date:
2023-02-27
Last Update Post Date Type:
ACTUAL